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Abstract
Background: The mechanisms that maintain sterility in the urinary tract are incompletely understood. Recent studies have
implicated the importance of antimicrobial peptides (AMP) in protecting the urinary tract from infection. Here, we
characterize the expression and relevance of the AMP human alpha-defensin 5 (HD5) in the human kidney and urinary tract
in normal and infected subjects.
Methodology/Principal Findings: Using RNA isolated from human kidney, ureter, and bladder tissue, we performed
quantitative real-time PCR to show that DEFA5, the gene encoding HD5, is constitutively expressed throughout the urinary
tract. With pyelonephritis, DEFA5 expression significantly increased in the kidney. Using immunoblot analysis, HD5
production also increased with pyelonephritis. Immunostaining localized HD5 to the urothelium of the bladder and ureter.
In the kidney, HD5 was primarily produced in the distal nephron and collecting tubules. Using immunoblot and ELISA
assays, HD5 was not routinely detected in non-infected human urine samples while mean urinary HD5 production increased
with E.coli urinary tract infection.
Conclusions/Significance: DEFA5 is expressed throughout the urinary tract in non-infected subjects. Specifically, HD5 is
expressed throughout the urothelium of the lower urinary tract and in the collecting tubules of the kidney. With infection,
HD5 expression increases in the kidney and levels become detectable in the urine. To our knowledge, our findings represent
the first to quantitate HD5 expression and production in the human kidney. Moreover, this is the first report to detect the
presence of HD5 in infected urine samples. Our results suggest that HD5 may have an important role in maintaining urinary
tract sterility.
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Introduction
The urinary tract, apart from the urethral meatus, is usually
sterile despite its proximity with fecal flora. The precise
mechanisms by which the urinary tract maintains its sterility are
not well understood. Proposed mechanisms contributing to
defense of the urinary tract include urine flow, alterations in urine
pH and osmolarity, regular bladder emptying, chemical-defense
components of the uroepithelium, and epithelial shedding/influx
of effector immune cells with bacterial stimulation [1]. In addition,
antimicrobial peptides (AMPs) have recently been shown to have
an important role in maintaining urinary tract sterility [2].
AMPs, which serve as natural antibiotics produced by nearly all
organisms, are a ubiquitous component of the innate immune
system. AMPs are cationic molecules expressed by phagocytic
white cells and epithelial cells. In humans and other mammals,
defensins are a major family of AMPs. Defensins typically have
broad-spectrum antimicrobial activity against gram-positive and
gram-negative bacteria, viruses, fungi, and protozoa [2,3].
Defensins are initially synthesized as preproproteins and undergo
processing to become mature, biologically active peptides [4]. In
humans, defensins are classified into one of two families depending
on their disulfide bridging pattern – the alpha-defensins or the
beta-defensins [5].
In the urinary tract, the beta-defensins are widely expressed
throughout the uroepithelium. Epithelial cells lining the kidney’s
loop of Henle, distal tubule, and collecting duct constitutively
express human beta-defensin 1 (hBD1). Although urinary levels of
hBD1 are insufficient to kill invading bacteria, hBD1 provides a
fast-acting antimicrobial coating of tubular lumens and prevents
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Recent studies indicate that the redox-state of hBD1 significantly
affects antimicrobial potency, such that the reduced peptide is
much more potent that the disulfide-linked oxidized form [7]. The
significance of this at the urothelial surface has not been
determined. Another defensin, human beta-defensin 2 (hBD2) is
not constitutively expressed in healthy kidney tissue; however,
hBD2 expression is induced by infection [8].
Unlike the beta-defensins, the role of epithelial-derived alpha-
defensins is not well described in the urinary tract. The expression
and function of alpha-defensin HD5 and HD6 have mostly been
reported in the small intestine where they are secreted by Paneth
cells into the intestinal crypts and contribute to the balance of
intestinal microbiotica [9]. HD5 has also been localized in the
male and female genital tracts, with evidence suggesting that it is
inducible and important in eradicating infection [10,11,12].
Urinary HD5 has been detected in patients who have undergone
ileal neobladder reconstruction and ileal conduit urinary diversion
whereby the source of HD5 production was primarily credited to
the ileal Paneth cells [13,14]. HD5 has antibacterial activity
against common uropathogenic gram-positive bacteria and gram-
negative bacteria [15]. HD5 also has antimicrobial activity against
uropathogenic viruses like adenovirus and BK virus [16,17,18]. In
this study, we provide the initial description and quantification of
HD5 expression in the human kidney and further define its
expression in the lower urinary tract during sterility and infection.
Results
DEFA5 mRNA is constitutively expressed in human
bladder, ureter, and kidney
Quantitative real-time PCR demonstrates that all tested
bladder, ureter, and kidney specimens without infection constitu-
tively expressed DEFA5. DEFA5 expression was significantly
greater in the lower urinary tract than the upper urinary tract
(p=0.014). In the bladder (n=4), mean DEFA5 expression was
4,656637 transcripts per 10 ng RNA and in the ureter (n=4)
mean DEFA5 expression was 4,1126170 transcripts per 10 ng
RNA (Figure 1A). In the kidney (n=6), mean DEFA5 expression
was 2,9376274 transcripts per 10 ng RNA. DEFA5 expression
was analyzed separately in the renal cortex, medulla, and pelvis.
DEFA5 expression did not significantly vary by kidney region
(p=0.45).
DEFA5 expression and HD5 peptide expression increase
with pyelonephritis
Quantitative real-time PCR analysis performed on kidney
tissues with pyelonephritis demonstrated a significant increase in
DEFA5 expression compared to non-infected kidney tissues. With
pyelonephritis (n=6), mean DEFA5 expression increased to
7,82961,052 transcripts per 10 ng RNA (p=0.019) (Figure 2A).
To further evaluate this increase in expression with pyelone-
phritis, we performed immunoblot analysis on the same kidney
tissue used for real-time PCR analysis to evaluate for concurrent
increases in HD5 peptide production (Figure 2B, middle panel).
Immunoblot analysis, using polyclonal HD5 antisera, demonstrat-
ed significantly greater HD5 peptide production in kidney tissues
with pyelonephritis (n=6) compared to non-infected kidney tissues
(n=6). Non-infected kidney tissues expressed 300625 ng HD5/
gram wet tissue weight while kidney tissue with pyelonephritis
expressed 600621 ng HD5/gram wet tissue weight (p,0.0001).
Blots were re-probed with GAPDH to serve as a loading control
(Figure 2B, middle panel) and a silver stain was also performed to
confirm equal protein loading (Figure 2B, top panel).
HD5 peptide is produced throughout the human kidney
and urinary tract
Immunostaining was performed to localize HD5 production in
the urinary tract. Immunohistochemistry (IHC) showed that HD5
immunoreactivity was present throughout the urothelium of the
ureter and bladder of all investigated specimens (n=4, Figure 3).
IHC also showed that HD5 was produced in tubules of the renal
cortex and medulla of all specimens (n=6, Figure 4). Immuno-
fluorescence (IF) demonstrated that HD5 expression was greatest
in the distal nephron and the collecting tubules (Figure 5). The
interstitium and glomeruli did not show HD5 immunoreactivity.
The immunostaining shown in Figures 3, 4, and 5 was performed
using a mouse monoclonal anti-HD5 antibody (8C8) that
recognizes the HD5 propeptide (Abcam, Cambridge, MA). Results
were similar when using rabbit polyclonal anti-HD5 antibody that
recognizes the HD5 propeptide and mature peptide (data not
shown) – suggesting that HD5 is stored as a propeptide.
With pyelonephritis, HD5 immunostaining markedly increased.
HD5 immunoreactivity increased throughout the proximal
nephron, the distal nephron, and the collecting tubules (Figure 4
and Figure 5). As in non-infected specimens, the glomeruli and
interstitium showed no HD5 expression with infection. Negative
controls showed no HD5 immunoreactivity.
Infected human urine contains measurable
concentrations of HD5 peptide
Immunoblot analysis, using rabbit polyclonal antiserum that
detects the precursor proHD5 and further processed forms
identified measurable levels of HD5 in 13 of the 15 tested urine
samples infected with uropathogenic E.coli (Figure 6A and B).
When present, HD5 levels, normalized to urine creatinine, ranged
from 299.8–669.7630 ng HD5/mg urine Cr (110.67 ng/mL–
276.67 ng/mL), which corresponds to 11.10–27.67 nmol/L. In
non-infected urine samples (n=15), HD5 was at or below the
detection limit of (,50 ng). Enzyme linked immunosorbant assay
(ELISA) on the same urine samples, using the mouse monoclonal
antibody (8C8) that detects only the precursor proHD5, detected
Figure 1. Expression of DEFA5 in human kidney, ureter, and
bladder. DEFA5 mRNA transcript levels were quantified by real-time
PCR in non-infected kidney, ureter, bladder. Shown are the results of
three independent samples. In the table below, the mean transcript
levels are shown with the SEM. DEFA5 expression was significantly
greater in the lower urinary tract (p=0.014).
doi:10.1371/journal.pone.0031712.g001
Alpha Defensin 5 Expression in the Urinary Tract
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31712Figure 2. HD5 expression increases with pyelonephritis. (A) DEFA5 mRNA transcript levels were quantified by real-time PCR in non-infected
kidney tissue and in kidney tissue with pyelonephritis. Shown are the results for three independent samples. In the table below, the mean transcript
levels are shown with the SEM. DEFA5 expression was significantly greater with pyelonephritis (p=0.019). (B) To confirm the increase in message is
accompanied by an increase in HD5 protein production, cationic peptides from the same non-infected kidney tissues (NL) and kidney tissue with
pyelonephritis (P) were subjected to SDS PAGE followed by Western immunoblot analysis. Each lane contained the equivalent of 800 mg of cationic
protein. Silver stained PAGE gels (top panel) confirmed equal protein loading into each lane. Immunoblot analysis for GAPDH and HD5 (middle
panel). Serial dilutions of proHD5 (200 ng–70 ng) were subjected to SDS PAGE followed by Western immunoblot analysis (bottom panel).
doi:10.1371/journal.pone.0031712.g002
Figure 3. HD5 is expressed throughout the urothelium of the ureter and bladder. Immunohistochemistry demonstrates HD5 expression
(brown/arrows) throughout the urothelium of the human bladder (A) and ureter (C). Immunostaining was most prominent in the luminal surfaces
(brown/arrows). Immunostaining was not detected in the smooth muscle layers of the bladder or ureter (+). Negative control bladder (B) and ureter
(D) showed no immunostaining. Magnification 206.
doi:10.1371/journal.pone.0031712.g003
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tested. Urinary proHD5 concentrations ranged from 122.78–
490.060.03 ng HD5/mg urine Cr (30.02 ng/mL–200.5 ng/mL)
when present (Figure 7).
Discussion
In this study, we provide the initial characterization HD5 in the
human kidney, ureter, and bladder. HD5 has been shown to be an
important AMP that prevents invasive infection in the intestine
and is up-regulated in the genital tract during infection
[11,18,19,20,21]. Epithelial derived AMPs, like HD5, have been
shown to be important in maintaining sterility in the urinary tract
[8,22,23,24]. Deficiencies in these innate mucosal defenses may
result in acute and/or chronic infection [25,26].
Our quantitative real-time PCR results demonstrate that
DEFA5 is constitutively expressed in human kidney, ureter, and
bladder. DEFA5 expression increases from the upper urinary tract
to the lower urinary tract – following the flow of the urinary
stream and the increasing closeness to the microbiota’s point of
invasion. To our knowledge, this is the first study to quantify
DEFA5 expression in the human kidney and bladder. Recently,
Townes et al demonstrated that normal distal ureter can express
DEFA5 [14]. Our results also suggest that DEFA5 is constitutively
expressed by the distal ureter. Although DEFA5 expression in the
urinary tract is nearly 100-fold lower than that found in
gastrointestinal tissues, basal uroepithelial expression of DEFA5 is
comparable to the expression of previously described urinary tract
AMPs like cathelicidin, hBD-1, hBD-2, and ribonuclease 7
[6,8,22,24,27].
In contrast to the mature gastrointestinal tract where DEFA5 is
expressed at high levels in both states of health and infection/
inflammation, our quantitative real-time PCR data demonstrate
that DEFA5 expression in the kidney is significantly up-regulated
with infection [27,28,29]. This inducible pattern of expression is
analogous to DEFA5 expression in the female reproductive tract
where DEFA5 expression increases with salpingitis [30]. In the
urinary tract, Townes et al have shown a trend toward greater
ureteral expression of DEFA5 in patients with UTIs who have
undergone ileal conduit urinary diversion [14].
Our immunoblot analysis complements the real-time PCR data
by demonstrating that HD5 peptide production increases with
pyelonephritis. This inducible pattern of HD5 production is
similar to that seen in some members of the beta-defensin family.
hBD2 shows an inducible pattern of production with infection of
the urinary tract and/or chronic pyelonephritis [8,31,32]. HD5
peptide production has been shown to increase in the upper
female genital tract and male urethra with inflammation [11,30].
Using immunostaining, we demonstrate that HD5 is uniformly
produced throughout the urothelium of the ureter and bladder.
Because the vast majority of UTIs result from fecal flora that
ascend into the bladder, these results suggest that HD5 expression
is present in locations where microbial exposure occurs most
frequently [33]. Therefore, HD5 is ideally positioned to prevent an
ascending microbial infection. In the kidney, HD5 is primarily
produced in the distal nephron and collecting tubule. These
findings suggest that HD5 is produced in locations where it will be
positioned to have optimal antimicrobial activity. Previous studies
have shown that the antimicrobial properties of defensins are
dependent on salt concentration – with higher salt concentrations
decreasing antimicrobial activity [23,34,35]. We speculate that the
low salt concentrations of the distal nephron and collecting tubule
provide a favorable milieu for HD5 antimicrobial activity.
Figure 4. HD5 production in non-infected human kidney and kidney with pyelonephritis. Immunohistochemistry demonstrates HD5
production in isolated renal tubules (brown/arrows) in non-infected renal cortex (A) and medulla (C). With pyelonephritis, HD5 production increased
in the renal tubules of the cortex (B) and medulla (D). The glomeruli (+) show no immunostaining in non-infected kidney samples and with
pyelonephritis. Negative controls showed no immunostaining (not shown). Magnification 206.
doi:10.1371/journal.pone.0031712.g004
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secreted into the urine at low levels. Given the size (8.1 kDa and
3.7 kDa) and positive charge of proHD5 and fully processed HD5,
it is possible that some urinary HD5 peptide originates, at least in
part, from plasma filtrate. Yet, there is little evidence suggesting
that HD5 persists in the plasma [27]. Additionally, to appear in
the urine, HD5 would need to escape the efficient peptide
absorption mechanisms in the proximal tubule [6,36]. Finally, the
urine samples used underwent centrifugation before the assays
were performed, removing cellular sources of HD5.
At the detected concentrations, urinary HD5 is unlikely to be
directly antimicrobial against uropathogenic microorganisms as
fully processed HD5 has a minimal inhibitory concentration (MIC)
between 6–10 mg/mL against common gram-negative uropatho-
genic bacteria [15]. However, mucosal surface concentrations are
likely to be higher. Furthermore, immunoblot analysis demon-
strates that HD5 concentrations are significantly greater in the
kidney. These results suggest that HD5 is involved in mucosal
defense of the urinary tract. An analogous pattern is seen with
hBD1, where urinary concentrations of hBD1 are insufficient to
exhibit antimicrobial activity but higher peptide concentrations
are detected near the renal tubules [6,31].
Because IHC demonstrates that proHD5 is a major form of
HD5 in the kidney and because both mature and proHD5 are
detected in the urine, we speculate that HD5 is primarily secreted
as a precursor molecule and then undergoes proteolytic processing
to generate mature forms – similar to the gastrointestinal and
genitourinary tracts [11,30,37]. In the small intestine, Paneth cells
produce trypsin, which cleaves the HD5 propeptide so that the
fully processed peptide is the predominant form in the intestinal
lumen [37]. In the male urethra, the key processing and activating
enzymes for HD5 are neutrophil proteases contributed by
Figure 5. Tubular HD5 expression in states of sterility and infection. Human kidney labeled for HD5 (green), nuclei (blue) and nephron
specific markers (red). Segment markers consisted of AQP-2 for collecting tubules (CT), THP for the loop of Henle (LOH), and AQP-1 for proximal
tubules (PT). A/B: HD5 (green) was produced in the collecting tubules (red apical AQP-2 staining) of non-infected kidney tissue (A) and with
pyelonephritis (B). Arrows indicate HD5 is produced in other nephron segments. C/D: HD5 (green) was expressed in the loops of Henle (red THP
staining) in non-infected kidney tissue (C) and with pyelonephritis (D). E/F: HD5 (green) shows minimal production in the proximal tubules (red AQP-
1 staining) of non-infected kidney tissue (E) and with pyelonephritis (F). Magnification 406.
doi:10.1371/journal.pone.0031712.g005
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tions of epithelial trypsinogen, urinary trypsin, and/or neutrophil
proteases on HD5 processing in the urinary tract during infection
remain to be determined. Moreover, the effects of changes in the
urinary environment on HD5 function (alterations in osmolarity,
pH, and cationic concentrations) also remain to be determined.
In conclusion, this is the first study to identify and quantitate the
expression and production of HD5 in the urinary tract. Our results
suggest that HD5 is an epithelial-derived AMP that may play an
important role in the innate immunity of the human uroepithe-
lium preventing the translocation of invading pathogens into the
circulation. Elucidation of the factors that regulate HD5
production may lend novel insight into the pathogenesis of UTIs
in patients at risk for UTIs and patients with chronic infections.
Methods
Study approval
Informed written consent was obtained from all patients
participating in this study. For subjects less than 18 year of age,
written parental/guardian consent was obtained. The Nationwide
Children’s Hospital (NCH) Institutional Review Board approved
this study along with the consent process and documents (IRB07-
00383).
Human Tissue and Urine Samples
Non-infected distal ureter and bladder tissue (n=4) was
obtained from children undergoing ureteral re-implantation for
reasons other than recurrent infection. Non-infected kidney
samples (n=6) were obtained from patients undergoing nephrec-
tomy for renal tumors. Tissue samples were free of microscopic
signs of disease or inflammation. Kidney tissue from patients with
chronic pyelonephritis was provided by the Cooperative Human
Tissue Network (n=6) [38]. Two independent pathologists
confirmed the histopathologic diagnosis of pyelonephritis. Tissue
samples were snap-frozen or preserved as neutral formalin-fixed
paraffin-embedded sections. Sections of non-infected kidney tissue
were dissected into cortex, medulla, or renal pelvis before storage
(n=4).
Non-infected and infected urines samples were obtained from
children presenting to the NCH emergency department or the
nephrology clinic. The diagnosis of a UTI was made by a positive
urine culture according to the American Academy of Pediatrics
Guidelines [39]. All infected urine samples had .10
6 CFU/mL of
E.coli. Urinary pH values ranged from 5.5 to 8.5 (mean urine
pH 6.9). Urinary ionic composition was not measured. Urine
samples were centrifuged to remove urine sediment, and protease
inhibitor cocktail was added (Thermo Scientific, Rockford, IL,
USA).
Ribonucleic Acid Isolation and Reverse Transcription
Total RNA was isolated from frozen tissue using the Promega
Total RNA Isolation System (Promega, Madison, WI, USA). For
cDNA synthesis, 4–8 mg of total RNA was reverse transcribed with
Superscript III reverse transcriptase using an oligo-(dT)12–18
primer according to the supplier’s protocol (Invitrogen, Carlsbad,
CA, USA).
Cloning of Gene Specific Plasmids for Standard Curves
The cDNA encoding DEFA5 and GAPDH were cloned into a 4-
Topo plasmid vector (Invitrogen) according to manufacturer’s
instructions. Plasmids were sequenced to confirm that the correct
Figure 6. HD5 is present in infected urine samples. HD5 levels in
sterile urine samples (n=15) and urine samples infected with
uropathogenic E.coli (n=15). Cationic peptides from non-infected urine
(NL) and infected urine (IN) were subjected to SDS PAGE followed by
Western immunoblot analysis. Each lane contained the equivalent of
300 mg of urinary cationic protein. (A) Silver stained PAGE gels with
150 ng ProHD5 as standard to confirm equal protein loading into each
lane. (B) Western blot analysis with 200 ng ProHD5 as standard.
doi:10.1371/journal.pone.0031712.g006
Figure 7. Urinary production of HD5 in infected urine samples.
HD5 levels in sterile urine samples and urine samples infected with
uropathogenic E.coli. The square boxes depict urinary proHD5
standardized to urine creatinine detected by ELISA assay using
monoclonal antibody 8C8. The open circles depict urinary proHD5
and mature HD5 standardized to urine creatinine by immunoblot
analysis. ProHD5 and mature HD5 were not detected in sterile urine
samples using polyclonal HD5 antisera.
doi:10.1371/journal.pone.0031712.g007
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were quantitated (by spectrophotometric absorbance at 260 nm
and ethidium bromide staining agarose gel electrophoresis) and
used in real-time PCR to generate standard curves for each
reaction.
Quantitative Real-time PCR
Quantitative real-time PCR was performed using single-
stranded cDNA from human kidney, ureter, and bladder tissue
with specific oligonucleotide primer pairs using the 7500 Real-
Time PCR System (Applied Biosystems, Carlsbad, CA, USA).
PCR exon junction spanning primers were designed and se-
quences were confirmed using DNAstarH Laser Gene SeqBuilder
(DEFA5 forward primer: 59- TCC CTC CTG CAG GTG ACC
CCA-39 and DEFA5 reverse primer 59-GTG GCT CTT GCC
TGA GAA CCT GA-39).
Briefly, cDNA corresponding to 10 ng RNA served as a
template in a 25 ml reaction containing 2.0 mM of each primer and
16Light-Cycler-Fast Start DNA Master SYBR Green mix. The
PCR conditions were: initial denaturation at 95uC for 10 minutes,
followed by 40 cycles with each cycle consisting of denaturation at
94uC for 30 seconds, annealing at 64uC for 30 seconds, and
extension at 72uC for 30 seconds. The cycle-to-cycle fluorescence
emission was monitored at 530 nm and analyzed using 7500
Software V2.0.3 (Applied Biosystems). Gene specific plasmid
standards were included with every set of reactions. As a positive
control, terminal ileum RNA was included with each set of
reactions and results were compared to previously published
standards [27].
To confirm PCR amplification of the intended product, a
representative sample was analyzed by electrophoresis on a 1.5%
agarose gel. The products were visualized by ethidium bromide
staining and compared to DNA size standards to confirm
anticipated product size (not shown). In addition, a melting
temperature profile curve of every PCR reaction was determined
at the end of each reaction.
HD5 Antibodies
The HD5 propeptide (AA20-94) and partially processed forms
(AA36-94 and 56–94) were identified using a commercially
available mouse monoclonal (8C8) anti-HD5 antibody (Abcam).
The HD5 propeptide and the mature peptide (AA63-94) were
identified using previously described rabbit polyclonal antiserum
[13,40].
Immunoblot
Sections of the same kidney specimens used for quantitative real
time PCR analysis (3–6 mg wet weight) were pulverized using a
mortar and pestle in liquid nitrogen and dissolved in RIPA buffer
with protease inhibitors. Urinary proteins were extracted from
urine samples using the Proteospin
TM Urine Protein Concentra-
tion Micro Kit (Norgen Biotek Corporation, Thorold, ON,
Canada). Kidney and urine protein concentrations were quantified
using a modified Bradford Assay and confirmed using an
OD280 nm reading. Equal concentrations of kidney tissue or
urinary protein were loaded onto 18% sodium dodecyl sulfate
gradient gels and subjected to electrophoresis. To ensure equal
protein loading, a silver stain was performed.
After electrophoretic separation, proteins were transferred onto
a nitrocellulose membrane. After fixation with 0.05% glutaralde-
hyde in TBS, the membranes were blocked in 5% fat-free milk for
30 to 60 minutes and incubated in a 1:1,000 dilution of rabbit
polyclonal HD5 antiserum overnight. After washing, the second-
ary antibody, an anti-rabbit horseradish peroxidase-conjugated
anti-rabbit IgG diluted 1:10,000 (Cell Signaling Technology,
Danvers, MA, USA), was applied for 1 hour at room temperature.
Immunoblots from kidney tissues were also probed with anti-
GAPDH antibody (Sigma Aldrich) for two hours at room
temperature and then incubated with the secondary antibody
described above. The proteins were visualized using and ECL
detection system and chemiluminescence film according to the
manufacturer’s instructions (BioExpress, Kaysville, UT, USA).
HD5 was quantitated by comparing resulting band intensities
with a serial dilution of recombinant standard proHD5 protein
(Peptides International, Louisville, KY, USA). Kidney HD5
concentrations were standardized to wet tissue weight. Urinary
HD 5 concentrations were divided by urine creatinine to establish
standardized urine HD5-to-creatinine ratios (mg/mg) to account
for urine dilution. Urine creatinine concentrations were deter-
mined using the Oxford Biomedical Research creatinine micro-
plate assay (Rochester Hills, Michigan, USA).
Immunohistochemistry
Following deparaffinization, rehydration, and antigen retrieval,
a biotin block and a serum-free protein block were performed
(Superblock, ScyTek Laboratories, Logan, UT, USA). The slides
were incubated overnight at 4uC with monoclonal mouse HD5
(8C8) antibody (1:200; Abcam) or rabbit polyclonal antiserum
(1:500) followed by anti-polyvalent biotinylated antibody and
UltraTek Streptavidin/HRP (ScyTek Laboratories). Sections were
developed using 0.1% diaminobenzidine tetrachloride with 0.02%
hydrogen peroxide and counterstained with hematoxylin. Nega-
tive controls sections were incubated with non-immune serum in
place of HD5 antibody.
Immunofluorescence
Double-labeled immunofluorescence was performed to help
localize HD5 expression in the kidney. The collecting duct was
double-labeled for principal cells with goat polyclonal anti-human
aquaporin-2 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) [41]. The loop of Henle was double-labeled with mouse
polyclonal anti-human uromodulin antibody (Sigma-Aldrich) and
the proximal tubule was double-labeled with goat polyclonal
antihuman aquaporin-1 (Santa Cruz) [41,42]. Rhodamine donkey
polyclonal anti-goat (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA), rhodamine goat anti-mouse (Jackson
ImmunoResearch Laboratories), and FITC donkey polyclonal
anti-rabbit (Santa Cruz) served as the secondary antibodies.
All sections were prepared as outlined above. They were
incubated with a mixture of mouse antisera against HD5 (1:200)
(Abcam), AQP-2 (1:500), uromodulin (1:500), AQP-1 (1:400) at
room temperature for 90 minutes. The secondary antibody was
applied for 90 minutes at room temperature and the sections were
mounted using mounting media with DAPI. Non-immune serum
was used as a negative control. The slides were examined with a
Leica DM4000B microscope and digitally photographed using
Spot RT camera/software (Diagnostic Instruments, Sterling
Heights, MI, USA).
ELISA
96-well flat-bottomed plates (Maxisorb, Nunc
TM, Rochester,
NY, USA) were coated overnight at 4uC with mouse monoclonal
antibody to HD5 (3 mg/mL) (Abcam). After blocking with
synthetic blocking buffer (Kem-En-Tec Diagnostics, Denmark),
100 mL standards and/or urine samples were added to the wells
and incubated for 2 hours at room temperature. Serial dilutions of
recombinant HD5 protein served as the standards (Novus
Biologicals). Following incubation with a biotinylated (Lightning-
Alpha Defensin 5 Expression in the Urinary Tract
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monoclonal antibody for 2 hours at room temperature, streptavi-
din-horse radish peroxidase (Biolegend, San Diego CA, USA) was
added for 30 minutes. After incubation with TMB substrate
solution for 15 minutes (Kem-En-Tec Diagnostics), the reaction
was terminated with STOP solution (Cell Signaling Technology,
Danvers, MA, USA) and read at a wavelength of 450 nm. HD5
concentrations from the ELISA assay were divided by urine
creatinine to establish standardized urine HD5-to-creatinine ratios
(mg/mg) to account for urine dilution as described above.
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